A panelist discusses how axatilimab, a humanized IgG4 monoclonal antibody targeting CSF-1 receptors on monocytes and macrophages, showed promising results in the AGAVE-201 trial for ...

The FDA approved belzutifan as the first oral therapy for advanced or metastatic pheochromocytoma and paraganglioma in ...

During a live event, Shuo Ma, MD, PhD, discussed the resistance mutation analysis of patients who had disease progression ...

During a live event, Karen Seiter, MD, discussed the role of the JAK/STAT pathway in myeloproliferative neoplasms and the use ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Christopher Schenewerk, MD, addresses the taboo topic of how to help health care professionals struggling with addiction.

Pedro C. Barata, MD, MSc, discusses options for metastatic hormone-sensitive prostate cancer in the community setting.

Data from the phase 2 ROME trial were presented by Andrea Botticelli, MD, during the ESMO Targeted Anticancer Therapies ...

Ciara Freeman, MD, PhD, discusses the challenges of incorporating anito-cel into the treatment protocol for patients with multiple myeloma.

Ariel Lopez-Chavez, MD, medical oncologist, director of precision medicine and developmental therapeutics at Allegheny Health Network Cancer Institute, discusses comprehensive genomic profiling and ...

A panelist discusses how neuroendocrine tumors are defined by World Health Organization (WHO) classification, graded based on ...

Adding pertuzumab to standard of care improved survival by 17% in patients with early-stage HER2-positive breast cancer.